




One-year findings from a prospective, real-world, multicenter study from Japan¹

Outcomes after treatment of a stenosed or occluded venous anastomosis of a synthetic arteriovenous (AV) access graft.

Sustained secondary patency at the target lesion and access circuit




No statistical difference in repeat interventions at the target lesion with respect to¹:

- Crossing the elbow
- Sex
- Number of prior interventions
- Diabetes
- Stent graft size and location
- Stenosis vs. occlusion
- Elephant trunk placement (stent graft in the outflow vein lies without vessel wall apposition)

^a As used by Gore, PROPATEN Bioactive Surface refers to Gore's proprietary CBAS® Heparin Surface.

VIABAHN® Device

One-year primary patency¹



65% **Target lesion primary patency**
in patients where the VIABAHN® Device was placed
across the elbow (N = 9) with no reported fractures.

1. Fukasawa M, Haruguchi H. A 1-year follow-up analysis of a post market surveillance study of a self-expanding endoprosthesis for stenosis or occlusion at the arteriovenous access. *Journal of Vascular Access*. In press. OPEN ACCESS <https://journals.sagepub.com/doi/10.1177/11297298251330951>



Consult Instructions
for Use
eifu.goremedical.com

Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx Only
Products listed may not be available in all markets.

© 2025 W. L. Gore & Associates GmbH. All rights reserved. All trademarks referenced are trademarks of either a member of the Gore group of affiliated companies or their respective owners. "Together, improving life" mark and design are trademarks of a Gore company. 25PL2226-EN01 JULY 2025

W. L. Gore & Associates, Inc.
goremedical.com

Asia Pacific +65 6733 2882 Australia/New Zealand 1800 680 424 Europe 00800 6334 4673
United States Flagstaff, AZ 86004 800 437 8181 928 779 2771

